New volume-forming drug for the treatment of stress urinary incontinence based on poly--caprolactone particles

The development of new methods and minimally invasive technologies for treating stress urinary incontinence in women is one of the most urgent problems of modern gynecology. The promising approaches is the use of periurethral administration of bulking agents that create additional volume in the field of transplantation and aimed at achieving an equilibrium pressure between the bladder and urethra. Thus bulking agents are capable for reducing the frequency of intra-and post-operative complications, as well as ensuring the most effective rehabilitation of patients. Bulking agent based on polycaprolactone particles obtained by the supercritical fluid method is proposed. This agent was compared with SUI Urodex® in an experimental model of stress urinary incontinence in in female SD rats. The analysis of the results showed that the bulking agent based on polycaprolactone particles has the same high efficiency in the treatment of urinary incontinence. The urodynamic index of LPP of a new bulking agent based on polycaprolactone particles is comparable to that for SUI Urodex®. Bulking agent based on polycaprolactone particles presumably has several advantages: such as a longer therapeutic effect (about 3 years) due to slow biodegradation in the body, lower cost pharmacological market due to production in Russia. Authors declare lack of the possible conflicts of interests.